A5084089404- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Immune cells in cancer
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Neuroblastoma Research and Treatments
- Nanoplatforms for cancer theranostics
- Pancreatic and Hepatic Oncology Research
- Ubiquitin and proteasome pathways
- Click Chemistry and Applications
- Biochemical and Molecular Research
- Sarcoma Diagnosis and Treatment
- Immune Response and Inflammation
- Peptidase Inhibition and Analysis
- Antimicrobial Peptides and Activities
- Chemokine receptors and signaling
- Protein Hydrolysis and Bioactive Peptides
University of South Bohemia in České Budějovice
2014-2025
Abstract Despite strides in immunotherapy, glioblastoma multiforme (GBM) remains challenging due to low inherent immunogenicity and suppressive tumor microenvironment. Converting “cold” GBMs “hot” is crucial for immune activation improved outcomes. This study comprehensively characterized a therapeutic vaccination strategy preclinical GBM models. The vaccine consists of Mannan‐BAM‐anchored irradiated whole cells, Toll‐like receptor ligands [lipoteichoic acid (LTA), polyinosinic‐polycytidylic...
Therapeutic options for metastatic pheochromocytoma/paraganglioma (PHEO/PGL) are limited. Here, we tested an immunotherapeutic approach based on intratumoral injections of mannan-BAM with toll-like receptor ligands into subcutaneous PHEO in a mouse model. This therapy elicited strong innate immunity-mediated antitumor response and resulted significantly lower volume compared to the phosphate buffered saline (PBS)-treated group significant improvement mice survival. The cytotoxic effect...
Abstract Background Autologous tumor cell-based vaccines (ATVs) aim to prevent and treat metastasis by activating patient-specific antigens induce immune memory. However, their clinical efficacy is limited. Mannan-BAM (MB), a pathogen-associated molecular pattern (PAMP), can coordinate an innate response that recognizes eliminates mannan-BAM-labeled cells. TLR agonists anti-CD40 antibodies (TA) enhance the antigen-presenting cells (APCs) present adaptive system. In this study, we...
Using killed microorganisms or their parts to stimulate immunity for cancer treatment dates back the end of 19th century. Since then, it undergone considerable development. Our novel approach binds ligands tumor cell surface, which stimulates phagocytosis. The therapeutic effect is further amplified by simultaneous application agonists Toll-like receptors. We searched that induce both a strong and are safe humans. B16-F10 murine melanoma model was used. For stimulation phagocytosis, mannan...
The application of the phagocytic receptor agonists in cancer immunotherapy was studied. Agonists (laminarin, molecules with terminal mannose, N-Formyl-methioninyl-leucyl-phenylalanine) were firmly anchored to tumor cell surface. When particular receptors used together LPS (Toll-like agonist), high synergy causing tumour shrinkage and a temporary or permanent disappearance observed. Methods anchoring (charge interactions, based on hydrophobic chains, covalent bonds) various regimes...
Abstract Emerging evidence is demonstrating the extent of T‐cell infiltration within tumor microenvironment has favorable prognostic and therapeutic implications. Hence, immunotherapeutic strategies that augment signature tumors hold promising potential. Recently, immunotherapy based on intratumoral injection mannan‐BAM, toll‐like receptor ligands anti‐CD40 antibody (MBTA) demonstrated potential to modulate immune phenotype injected tumors. The strategy promotes phagocytosis cells facilitate...
Cancer immunotherapy has shown remarkable clinical progress in recent years. Although age is one of the biggest leading risk factors for cancer development and older adults represent a majority patients, only few new immunotherapeutic interventions have been preclinically tested aged animals. Thus, lack preclinical studies focused on age-dependent effect during could lead to different therapeutic outcomes young animals future modifications human trials. Here, we compare efficacy previously...
Immunotherapy has become an essential component in cancer treatment. However, the majority of solid metastatic cancers, such as pheochromocytoma, are resistant to this approach. Therefore, understanding immune cell composition primary and distant tumors is important for therapeutic intervention diagnostics. Combined mannan-BAM, TLR ligand, anti-CD40 antibody-based intratumoral immunotherapy (MBTA therapy) previously resulted complete eradication murine subcutaneous pheochromocytoma...
Abstract Despite advances in immunotherapy, glioblastoma multiforme (GBM) remains challenging to treat due its low inherent immunogenicity and a suppressive tumor microenvironment. Converting “cold” GBMs “hot” tumors is crucial for effective immune activation improved patient outcomes. We comprehensively characterized the rWTC-MBTA autologous cancer vaccine, consisting of Mannan-BAM-anchored irradiated whole cells, Toll-like receptor ligands (LTA, Poly(I:C), R-848), an anti-CD40 agonistic...
The aim of this study was to evaluate the effectiveness individual (inactive) proenzymes and mixtures thereof in cancer treatment compare with more frequently used therapy based on active proteases. Experiments focused explanation possible mechanisms proenzyme action against tumours are included.Proenzyme sarcoma S-180 significantly reduced tumour growth prolonged survival mice. effect trypsinogen chymotrypsinogen synergistic. Proenzyme melanoma B16-F10 bearing mice both prevalence...
Abstract Immunotherapy based on activation of innate immunity has been tested in syngeneic mouse tumor models via intratumoral administration the following components: phagocytosis-stimulating ligands (Mannan-BAM), toll-like receptor (TLR) agonists, and immunostimulant anti-CD40 antibody (abbreviated as MBTA). In this study, colon carcinoma (CT26) glioma (GL261) were established to assess MBTA’s efficacy generating immune responses against distal metastatic lesions CNS tumors. Additionally,...
Abstract Despite the advances made in cancer treatment over past decades, one statistic has remained unchanged: metastatic accounts for 90 percent of annual deaths United States. Our group previously demonstrated that an autologous whole tumor cell vaccine (rWTC-MBTA: irradiated cells pulsed with Mannan-BAM, TLR ligands, and anti-CD40 antibody) had a potent anti-tumor immune response prolonged survival mouse colon carcinoma model. To investigate whether rWTC-MBTA would work “cold” models, we...
Abstract Despite numerous therapeutic advances in cancers, the treatment of glioblastoma multiforme (GBM) remains a challenge. Boosting T-lymphocyte mediated responses against GBM offers promising approach towards solving this problem. Herein, we present vaccination strategy that promotes phagocytosis tumor cells, enhances antigen presentation, and induces tumor-specific adaptive immune response with subsequent eradication. This consists subcutaneous injection irradiated whole cells (rWTC)...